The rise in hypertension has been a serious cause of concern in underdeveloped, developing and developed countries alike. Hypertension can lead to complications such as myocardial infarction, renal failure, stroke, and even death if not treated in a timely manner. Detection of hypertension is being increasingly focused by both private and public healthcare bodies, especially amongst young adults. In India, for instance, the total number of individuals with hypertension is projected to reach around 213 million by 2025. Furthermore, hypertension has been identified as the key reason for around 57% of stroke-related deaths in the country. Management of hypertension is facilitated through the use of cilnidipine-based drugs. Cilnidipine helps in the reduction of hypertension by blocking norepinephrine release, which in turn leads to vasodilatation and increase in renal blood flow. Heart rate is also drastically reduced due to the calcium-blocking action of Cilnidipine. These tablets are also available at an affordable cost, which helps in increasing its adoption amongst individuals, especially in developing economies. The growing demand for efficient management of hypertension using economic solutions is leading to the growth of the global cilnidipine market.
Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=803
The COVID-19 pandemic has severely affected the lives of individuals across the globe. Countries have been forced to observe lockdowns to prevent the spread of coronavirus. As a result of the same, numerous jobs have been terminated due to drying up of business activities and revenue. Studies have shown that stress, anxiety and hypertension amongst individuals have seen a significant spike in the last 12 months due to issues such as job loss, salary cuts and social isolation, amongst others. Cilnidipine, which falls under the category of calcium channel blocker (CCB) drug class, is used as a first line drug for hypertension management. Hence, the pandemic is expected to have a positive impact on the global cilnidipine market, as physicians are recommending cilnidipine-based drugs for management of hypertension which has been worsened by the pandemic.
The detailed research study provides qualitative and quantitative analysis of cilnidipine market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries/regions such as Europe, China, India, South Korea, and Japan.
Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=803
Key Findings of the Report:
- In terms of revenue, the global cilnidipine market was valued at US$ 9802.50 Mn in 2020 and is expected to reach US$ 48552.98 Mn by 2029, growing at a CAGR of 19.52% over the forecast period (2021 – 2029).
- In terms of regions, Europe accounted for the highest share in the global cilnidipine market in 2020. The rising awareness amongst individuals regarding the importance of handling hypertension, and heart-related stress, coupled with government measures that ensures the easier availability of cilnidipine in the European Union is a major reason for the higher share of Europe in the global Cilnidipine market. However, India is expected to show the highest growth during the forecast years in the global cilnidipine market, with an expected CAGR of 20.21%.
- 10 mg tablet doses were the most popular Cilnidipine-based drug in 2020. The ease in manufacturing of standardized 10 mg tablets is prompting the market participants to produce these tablets on a wider scale. Medley Pharma, for instance, manufactures Cilnidipine-based Cildip 10 Mg tablets which are available both online and offline in India. However, combinational doses are expected to show the fastest growth during the forecast years in the global cilnidipine market. Experimentation regarding the dose requirement based on factors such as age, hypertension levels, physical nature and activities, allergies, etc., are being performed by researchers to provide personalized drug doses which will help in furthering the impact of cilnidipine on issues such as anxiety and hypertension management.
- Some of the players operating in the cilnidipine market are Abbott, Ajanta Pharma Ltd, Alembic Pharmaceuticals Ltd, Alkem Laboratories Ltd, Eris Lifesciences Ltd, Fuji Viscera Pharmaceutical Company and Ajinomoto Intas Pharmaceuticals Ltd, J B Chemicals and Pharmaceuticals Ltd, Lupin Ltd, Macleods Pharmaceuticals Pvt Ltd, Mankind Pharma Ltd, Medley Pharmaceuticals, Micro Labs Ltd, Niksan Pharmaceutical, Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Trumac Healthcare, ZydusCadila, amongst others.
Request for Customization@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=803
Global Cilnidipine Market:
- By Treatment
- High Blood Pressure (Hypertension)
- Prevent Heart Attacks and Strokes
- Prevent Angina (Heart-Related Chest Pain)
- Decrease Protein Leakage from the Kidney in Patients who Have Diabetes
- Others
- By Doses
- 10mg Tablet
- Combination Doses
- By Region
- China
- Japan
- Korea
- Europe
- India
Get Full Information of this premium report@ https://www.absolutemarketsinsights.com/reports/Cilnidipine-Market-2021---2029-803
About Us:
Absolute Markets Insights strives to be your main man in your business resolve by giving you insight into your products, market, marketing, competitors, and customers. Visit …
Contact Us:
Email id: [email protected]
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424